Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis

ConclusionDPP ‐4 characterizes a population of activated fibroblasts and shows that DPP‐4 regulates TGFβ‐induced fibroblast activation in the fibrotic skin of SSc patients. Inhibition of DPP4 exerts potent antifibrotic effects when administered in well‐tolerated doses. As DPP4 inhibitors are already in c linical use for diabetes, these results may have direct translational implications for the treatment of fibrosis in patients with SSc.

Source: Arthritis and Rheumatology - December 26, 2019 Category: Rheumatology Authors: Alina Soare, Hermina A. Gy örfi, Alexandru E. Matei, Clara Dees, Simon Rauber, Thomas Wohlfahrt, Chih‐Wei Chen, Ingo Ludolph, Raymund E. Horch, Tobias Bäuerle, Stephan Hörsten, Carina Mihai, Oliver Distler, Andreas Ramming, Georg Schett Tags: Original Article Source Type: research